文献速递乳腺外科

初诊IV期乳腺癌原发灶手术切除的当代实践模式与生存分析

Surgical Resection of the Primary Tumor in Women With De Novo Stage IV Breast Cancer: Contemporary Practice Patterns and Survival Analysis.
PubMed 文献 · Ann Surg · 2019-01-01

基于美国国家癌症数据库2003至2012年诊断的24015例临床IV期乳腺癌女性,分析原发灶手术切除模式及其与总生存的关联。结果显示43.8%接受手术切除,手术(无论先于或后于系统治疗)与调整后总生存改善独立相关,且系统治疗后再手术的比例增加。

要点

  • IV期乳腺癌中43.8%接受原发灶手术,手术与调整后总生存改善独立相关。
  • 先系统治疗后手术者肿瘤更大(中位4.5 vs 3.1 cm)且全乳切除比例更高(81.4% vs 52.2%)。
  • 手术决策应个体化,多学科协作在转移性乳腺癌中仍高度相关。

核心结论

  • 原发灶手术切除与IV期乳腺癌调整后总生存改善独立相关(先手术HR 0.68,95%CI 0.62-0.73;系统治疗后手术HR 0.56,95%CI 0.52-0.61;P<0.001)。

研究设计与样本

  • 回顾性队列研究,数据来自美国外科医师学会国家癌症数据库,纳入2003至2012年诊断的临床IV期乳腺癌女性24015例。
  • 纳入分析者为诊断后12个月仍存活且原发肿瘤完整者,按治疗顺序分为先手术、先系统治疗、仅系统治疗三组。

主要发现

  • 24015例中56.2%(13505例)仅接受系统治疗,43.8%(10510例)接受手术切除。
  • 手术率随时间略降,2003年为43.1%,2011年为41.9%。
  • 与先手术者相比,先系统治疗后手术者肿瘤更大(中位4.5 vs 3.1 cm,P<0.001)且接受全乳切除比例更高(81.4% vs 52.2%,P<0.001)。

临床怎么用

  • 对诊断后存活超过1年的IV期乳腺癌患者,原发灶手术可作为个体化选择,尤其在与系统治疗序贯安排时。
  • 手术决策应经多学科团队讨论,综合考虑肿瘤负荷与系统治疗反应。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: We evaluated patterns of surgical care and their association with overall survival among a contemporary cohort of women with stage IV breast cancer. BACKGROUND: Surgical resection of the primary tumor remains controversial among women with stage IV breast cancer. METHODS: Women diagnosed with clinical stage IV breast cancer from 2003 to 2012 were identified from the American College of Surgeons National Cancer Database. Those with intact primary tumors who were alive 12 months after diagnosis were categorized by treatment sequence: (1) surgery before systemic therapy, (2) systemic therapy before surgery, and (3) systemic therapy alone. Multivariate logistic regression was used to estimate the association of treatment sequence with surgery type. Overall survival was estimated using multivariate Cox proportional hazards models. RESULTS: Among 24,015 women, 56.2% (13,505) underwent systemic therapy alone and 43.8% (10,510) underwent surgical resection. Rates of surgery decreased slightly over time (43.1% in 2003 to 41.9% in 2011). Treatment with systemic therapy before surgery was associated with larger tumor size (median 4.5 vs 3.1 cm, P < 0.001) and receipt of mastectomy (81.4% vs 52.2%, P < 0.001) when compared to those who underwent surgery first. Receipt of surgery, whether before or after systemic therapy (Hazard Ratio, 0.68; 95% confidence interval, 0.62-0.73; Hazard Ratio, 0.56; 95% confidence interval, 0.52-0.61; P < 0.001), was independently associated with improved adjusted overall survival when compared to systemic therapy alone. CONCLUSIONS: Surgical resection of the primary tumor occurs in almost half of women with stage IV breast cancer alive 1 year after diagnosis, and is increasingly occurring after systemic therapy. Coordinated multidisciplinary care remains highly relevant in the setting of metastatic breast cancer, where surgical decisions should be made on an individual basis and may affect survival in select women.

来源:Ann Surg,查看原文。版权归原作者所有。

引用

  1. Lane WO, Thomas SM, Blitzblau RC, et al. Surgical Resection of the Primary Tumor in Women With De Novo Stage IV Breast Cancer: Contemporary Practice Patterns and Survival Analysis. Ann Surg. 2019. PMID: 29227346. doi:10.1097/SLA.0000000000002621

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。